Schneiderman Daniel H 4
4 · AzurRx BioPharma, Inc. · Filed Jul 20, 2020
Insider Transaction Report
Form 4
Schneiderman Daniel H
CHIEF FINANCIAL OFFICER
Transactions
- Other
Stock option (right to buy)
2020-07-16−35,006→ 300,000 totalExercise: $1.03Exp: 2030-01-02→ Common Stock, par value $0.0001 per share (35,006 underlying) - Award
Stock option (right to buy)
2020-07-16+35,006→ 35,006 totalExercise: $0.85Exp: 2030-07-15→ Common Stock, par value $0.0001 per share (35,006 underlying) - Award
Stock option (right to buy)
2020-07-16+250,000→ 250,000 totalExercise: $0.85Exp: 2030-07-15→ Common Stock, par value $0.0001 per share (250,000 underlying)
Footnotes (4)
- [F1]On July 16, 2016, the board of directors of AzurRx BioPharma, Inc. (the "Company") determined to amend and restate a stock option award previously made to Mr. Schneiderman on January 2, 2020, to reduce the amount of shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), issuable upon exercise of such option to be the maximum number of shares Mr. Schneiderman was eligible to receive under the Company's 2014 Omnibus Equity Incentive Plan (the "Plan") on the original grant date (or 300,000 shares), due to certain limitations relating to Section 162(m) of the Internal Revenue Code that have since been eliminated from the Plan. Mr. Schneiderman was simultaneously awarded a replacement stock option covering the balance of shares intended to be issued at that time (or 35,006 shares).
- [F2]The stock option vests in 36 equal monthly installments over a term of three (3) years beginning on February 3, 2020, conditioned on Mr. Schneiderman's continued employment by the Company on the applicable vesting date.
- [F3]The stock option was accelerated to vest in 36 equal monthly installments over a term of three (3) years beginning on February 3, 2020, conditioned on Mr. Schneiderman's continued employment by the Company on the applicable vesting date.
- [F4]The stock option vests in 36 equal monthly installments over a term of three (3) years beginning on August 16, 2020, conditioned on Mr. Schneiderman's continued employment by the Company on the applicable vesting date.